Results 151 to 160 of about 578,043 (298)

Cangrelor Dosing, Administration, and Clinical Outcomes for Patients Undergoing Complex and High‐Risk Percutaneous Coronary Interventions

open access: yesCatheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Cangrelor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), with the advantage of rapid onset and offset. However, premature discontinuation may increase the risk of acute thrombosis for patients undergoing complex/high‐risk PCI (CHIP).
Siyu Ma   +8 more
wiley   +1 more source

Antimicrobial Peptides and Peptidomimetics in Foods – A Synthetic Foray

open access: yesChemFoodChem, EarlyView.
This Review discusses AMPs in foods and their syntheses. It espouses facile methods to make them accessible and suggests their utility in the mitigation and eradication of the burgeoning maladies of antimicrobial and multidrug resistance (AMR and MDR).
Josephat U. Izunobi   +2 more
wiley   +1 more source

Triglyceride Polygenic Score Identifies Individuals Who May Respond Differently to Aspirin in Primary Prevention

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Low‐dose aspirin is no longer routinely recommended for the primary prevention of cardiovascular disease in older adults due to a lack of net benefit over bleeding risk. We hypothesized that genetic subgroups may experience differential harm or benefit from aspirin therapy.
Peter D. Fransquet   +8 more
wiley   +1 more source

Dispensing of actionable pharmacogenetic drugs among adults receiving cardiovascular disease medications in the Northern Netherlands: A serial cross‐sectional study

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
The extent of pharmacogenetic (PGx) drug dispensing among Dutch adults receiving medications for cardiovascular disease (CVD) is unknown. Using the University of Groningen IADB.nl pharmacy database, we performed a serial cross‐sectional study (2019–2023) to estimate the annual prevalence of PGx drug dispensing and annual rates of initiation.
Zhuolin Zhang   +5 more
wiley   +1 more source

Reprocessing Mass Spectra from Therapeutic Drug Monitoring to Unveil Proton Pump Inhibitor Use and Quantify Phenoconversion of Escitalopram Metabolism in CYP2C19‐Genotyped Patients

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Escitalopram is a frequently prescribed antidepressant drug. CYP2C19 genotype is a major determinant of escitalopram metabolism and treatment outcome. However, real‐life studies show a high degree of genotype–phenotype mismatch in escitalopram metabolism.
Kristine Hole   +3 more
wiley   +1 more source

Navigating the Role of Clinical Pharmacists in Integrative Oncology Care Teams: Time to Create Higher Training and Practice Standards

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Integrative oncology (IO) programs are committed to offer evidence‐based complementary medicine within conventional cancer care, addressing quality of life‐related concerns. As part of a multidisciplinary team, clinical pharmacists provide guidance on potential effectiveness and safety of herbal supplement use, identifying potential toxicities and herb–
Eran Ben‐Arye   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy